Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-κB and STAT3 pathways highlighting mechanisms of immune evasion and potential for combination therapy
EV is associated with increased PD-L1 expression, along with upregulation of NF-κB and STAT3, suggesting a mechanistic link that may contribute to immune modulation in nectin-4-high bladder cancer cells. These findings highlight the need for combination strategies integrating EV with PD-1/PD-L1 inhibitors to optimize therapeutic outcomes in UC.
Authors
- Rikiya Taoka (ORCID: https://orcid.org/0000-0003-3243-499X)
- Akram Hossain (ORCID: https://orcid.org/0000-0002-5252-5138)
- Hirohito Naito (ORCID: https://orcid.org/0000-0002-1045-1978)
- Mikio Sugimoto (ORCID: https://orcid.org/0000-0001-9266-782X)
- Yohei Abe (ORCID: https://orcid.org/0000-0003-2519-4924)
- Xia Zhang (ORCID: https://orcid.org/0000-0003-3508-2061)
Institutions
- Kagawa University (JP)
Publication Details
- Journal
- BMC Immunology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1186/s12865-025-00751-2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00